Bio-Rad Introduces Enhanced Options with its IH-Co

HERCULES, CA--(Marketwired - May 24, 2017) - Bio-Rad Laboratories, Inc. ( NYSE : BIO ) ( NYSE : BIOb ), a global provider of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for enhanced capability with its IH -Com data management software to manage patient results with the company's IH -1000 automated blood typing instrument.

The IH -1000 blood typing instrument and a wide variety of associated gel cards have been commercially available in the U.S. since October 2016. IH -Com is a powerful data management tool that combines all current and prior results associated with a patient and delivers an overall interpretation and crosscheck. IH -Com can link instruments together at a lab and at other locations as well, and it facilitates the transfer of data to a laboratory information system (LIS). With the most recent clearance, users have additional options to automate the release of test results to the laboratory's LIS system, while continuing to ensure safe and accurate patient results. 

"We are pleased that the FDA has cleared our IH -Com data management software with expanded options for our customers in the U.S," said John Hertia, Bio-Rad Executive Vice President and President, Clinical Diagnostics Group. "The expanded options can lead to a more rapid and efficient delivery of safe and accurate patient results, significant workflow improvements, and overall a more lean laboratory operation."

About Bio-Rad Bio-Rad Laboratories, Inc. ( NYSE : BIO ) ( NYSE : BIOb ) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The Company employs more than 8,250 people worldwide and had revenues exceeding $2 billion in 2016. For more information, please visit www.bio-rad.com .

Bio-Rad Forward-Looking Statements This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding plans to introduce new products and the opportunities that may result from such new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.